Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -22.53M
March 31, 2026 -16.05M
December 31, 2025 -12.32M
September 30, 2025 -9.838M
June 30, 2025 -13.03M
March 31, 2025 -13.95M
December 31, 2024 -6.313M
September 30, 2024 -7.038M
June 30, 2024 -5.947M
March 31, 2024 -8.934M
December 31, 2023 -9.222M
September 30, 2023 -12.23M
June 30, 2023 -10.65M
March 31, 2023 -13.90M
December 31, 2022 -11.41M
Date Value
September 30, 2022 -10.98M
June 30, 2022 -13.97M
March 31, 2022 -13.95M
December 31, 2021 -12.29M
September 30, 2021 -9.121M
June 30, 2021 0.8371M
March 31, 2021 -12.47M
December 31, 2020 -9.679M
September 30, 2020 -8.406M
June 30, 2020 -16.06M
March 31, 2020 -18.08M
December 31, 2019 -16.61M
September 30, 2019 -8.642M
June 30, 2019 -11.43M
March 31, 2019 -14.73M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
InMed Pharmaceuticals, Inc. -2.909M
NervGen Pharma Corp. -4.086M
Appili Therapeutics, Inc. -0.0267M
Clearmind Medicine, Inc. -1.859M
Lexaria Bioscience Corp. -1.635M